<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376427</url>
  </required_header>
  <id_info>
    <org_study_id>LAL-07OPH</org_study_id>
    <nct_id>NCT01376427</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged &gt; 55 Years</brief_title>
  <official_title>PROTOCOL TREATMENT for Acute Lymphoblastic Leukemia Ph '(BCR / ABL) POSITIVE PATIENTS AGED&gt; 55 YEARS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to provide adequate treatment and is based on current scientific evidence&#xD;
      for elderly patients with ALL Bcr / Abl positive.&#xD;
&#xD;
      To determine whether low-dose chemotherapy associated with imatinib or dasatinib has&#xD;
      acceptable tolerability in elderly patients.&#xD;
&#xD;
      To determine whether this association can increase the rate and quality of referrals to the&#xD;
      results of the literature of imatinib as monotherapy for elderly patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prephase (days -5 to -1) Dexamethasone 10 mg/m2 bolus day EV for 5 days (-5 to -1).&#xD;
&#xD;
      Intrathecal treatment (diagnosis and prophylactic / therapeutic) -5 days:&#xD;
&#xD;
      Methotrexate 12 mg&#xD;
&#xD;
      Systemic treatment:&#xD;
&#xD;
        -  Imatinib 400 mg daily and continuous VO.&#xD;
&#xD;
        -  Vincristine (VCR) 1 mg (absolute dose) EV 1, 8, 15 and 22.&#xD;
&#xD;
        -  Dexamethasone (DEX): 10 mg/m2 EV, IM or PO days 1-2, 8-9 days 15-16, 22-23. .&#xD;
&#xD;
      Intrathecal chemotherapy:&#xD;
&#xD;
      Triple therapy was administered with methotrexate (MTX), cytosine arabinoside (ARA-C) and&#xD;
      hydrocortisone, days 1, 8, 15 and 22 (five doses total prophylactic between prophase and&#xD;
      induction):&#xD;
&#xD;
      MTX 12 mg ARA-C 40 mg Dexamethasone 4 mg&#xD;
&#xD;
      Maintenance during the first year will start after full recovery after induction and after&#xD;
      complete reassessment of the disease (including mielograma and Bcr-Abl/Abl or Bcr-Abl/Gus&#xD;
      ratio in peripheral blood) and will last until one year from the time of complete remission.&#xD;
&#xD;
      The basic treatment included imatinib 400 mg / day (or dasatinib), mercaptopurine at doses of&#xD;
      50 mg/m2 PO day and methotrexate 20 mg/m2 IM weekly.&#xD;
&#xD;
      One week every 3 months maintenance treatment added a &quot;mini-reinduction&quot; consisting&#xD;
&#xD;
        -  VCR: 1 mg (absolute dose), i.v., day 1.&#xD;
&#xD;
        -  Dexamethasone 40 mg / day, i.v. or p.o., days 1-2.&#xD;
&#xD;
        -  not considered more doses of triple intrathecal therapy. Reinduction only be practiced&#xD;
           during the first year after remission, so a total of 4 quarterly.&#xD;
&#xD;
      Maintenance treatment of second year&#xD;
&#xD;
      After the first year of maintenance will perform a complete reassessment of the disease&#xD;
      (including myelogram) and if the patient remains in complete remission maintenance will&#xD;
      continue (without reinduction) until two years from the time of diagnosis.&#xD;
&#xD;
      Maintenance treatment of third year During the third year after complete remission imatinib&#xD;
      administered alone (or dasatinib&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2007</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of response rate</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events treated with chemotherapy and dasatinib combination</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia Ph Positive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adults over 55 years diagnosed with acute lymphoblastic leukemia Ph 'positive (Bcr / Abl&#xD;
        positive) and previously untreated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other LAL negative for t (9; 22) and Bcr / Abl.&#xD;
&#xD;
          2. biphenotypic acute leukemias or bilinear with t (9; 22).&#xD;
&#xD;
          3. blast crisis of chronic myeloid leukemia progression during or after polychemotherapy&#xD;
             treatment (including allo-BMT) or with inhibitors of tyrosine kinases.&#xD;
&#xD;
             The criteria for exclusion from treatment (but not patient record) any of the&#xD;
             following&#xD;
&#xD;
          4. General condition affected (grades 3 and 4 WHO scale), not attributable to the LAL.&#xD;
&#xD;
          5. Lack of consent by the patient to use their clinical d&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol and all Hospital Pethema</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose MÂª Ribera, Dr</last_name>
      <email>jribera@iconcologia.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.fundacionpethema.es/</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

